Today's story
Imfinzi Bladder Combo Wins FDA Priority Review
Up to half of muscle-invasive bladder cancer patients cannot take standard chemo. FDA gave Priority Review to AstraZeneca's IMFINZI-enfortumab combo for them; decision due Q4 2026.
Health · 10 sources · Sep 25, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About enfortumab vedotin
Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate used for the treatment of urothelial cancer. It is a nectin-4-directed antibody and microtubule inhibitor conjugate. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.
Everything about enfortumab vedotin →